search icon
  • Print
  • ShareThis
  • Text Size
  • Federal Funding for Infectious Diseases Programs


    Today’s investment in ID research; public health and prevention; and development of new drugs, vaccines and diagnostics will pay significant dividends in the future. Such investments can prevent needless deaths, dramatically reduce health care costs, and improve the quality of life for millions of Americans and others around the world.  IDSA supports appropriate funding for domestic and international programs including those at the:

    • National Institute for Allergies and Infectious Diseases 
    • Centers for Disease Control and Prevention  
    • Food and Drug Administration 
    • Health Resources Services Administration 
    • U.S. Agency for International Development 
    • National Institute of Health’s Fogarty International Center 


    IDSA’s funding priorities include antimicrobial resistance; immunizations; drug, vaccine and diagnostics development; and HIV/AIDS and tuberculosis prevention and treatment.


    See also:

    HIVMA Federal Funding

    IDSA's Efforts in Advocating for Appropriate Federal Funding for Infectious Diseases Programs


    IDSA Statement on Passage of Continuing Resolution and Zika Funding

    The Infectious Diseases Society of America (IDSA) welcomes the action taken by Congress to prevent a government shutdown and provide $1.1 billion for responses to the continuing spread of the Zika virus. The full and continuous operation of Federal agencies, including the Centers for Disease Control and Prevention and the National Institutes of Health, is critical to our nation’s safety and wellbeing. Additionally, the overdue resources the bill provides for global and domestic Zika responses must be put to work immediately.

    IDSA Urges Congress to Support Research on ID Reimbursement (PDF)

    At the request of IDSA, the Senate Appropriations Committee approved a provision in their FY 2017 spending bill for health programs that asks the Center for Medicare & Medicaid Services to examine the codes used by ID physicians to obtain reimbursement for evaluation and management services to make certain that they reflect the value provided patients.

    IDSA Provides Testimony to House and Senate Spending Panels on 2017 Budget (PDF)

    IDSA provided testimony to the House and Senate subcommittees that oversee spending on health programs.  The statement largely focused on federal efforts to combat the Zika virus and antimicrobial resistance.

    Need for Antibiotic Resistance Funding Featured in Testimony on FY 2016 (PDF)

    IDSA provided testimony on 2016 funding for infectious diseases priorities to the House subcommittee that has oversight of health spending. The need for funding to implement the National Action Plan for Combating Antibiotic-Resistant Bacteria was featured in the statement.

    IDSA Joins Plea for Emergency Zika Funding Ahead of Congressional Recess (PDF)

    In a letter to House and Senate leaders, IDSA and other health groups called on Congress to advance an emergency funding bill to address Zika before the summer recess that begins in mid-July.

    IDSA Joins More than 160 Groups in Supporting Senate Push for Mandatory NIH Funding (PDF)

    In a letter organized by Research!America, IDSA and over 160 other groups asked leaders of the Senate's health committee to add mandatory funding for the National Institutes of Health to a biomedical innovations package that has been moving through the panel over the last three months.

    IDSA Joins Groups in Advocating for Zika Funding (PDF)

    IDSA and 66 other groups joined a letter to leaders in Congress, organized by the March of Dimes, in support of the administration's $1.9 billion emergency spending request to address Zika.

    Nearly 50 Groups Join IDSA in Call for Sustained Investments in Federal AR Efforts (PDF)

    IDSA and 47 other groups joined in a letter to House and Senate appropriators urging continued funding for programs within the Department of Health and Human Services that are a part of the National Action Plan for Combating Antibiotic-Resistant Bacteria.

    Groups Seek Support for Global TB Activities in Anticipation of FY2014 Funding Bill Release (PDF)

    IDSA joined other stakeholders in a letter to Congress seeking $236 million for USAID's TB programs in FY2014.  The letter discusses the impact of TB around the globe and makes special note of the emergence of multidrug-resistant and extensively drug-resistant TB.  USAID is a central partner in efforts to control TB in the world's 30 most highly burdened countries.

    Community Letter Advocating Robust Global Health Efforts (PDF)

    IDSA joined 53 other organizations to urge lawmakers to maintain its funding commitments to improving health in developing countries, without cutting other broader humanitarian efforts and development or imposing any new policy restrictions.

    TB Coalition Letter for Global and Domestic TB Funding (PDF)

    IDSA joined 16 other organizations to urge lawmakers to strengthen U.S. leadership in the fight against TB as envisioned in the Lantos-Hyde Act and Comprehensive TB Elimination Act by investing in global and domestic TB programs at USAID and CDC.

| HIVMA | Contact Us

© Copyright IDSA 2016 Infectious Diseases Society of America

Full Site Mobile Site